Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Tesamorelin Help Metabolic Syndrome Research: FDA-Approved vs Off-Label Use

FDA-Approved Use HIV-associated lipodystrophy (excess abdominal fat) Limited to HIV population with documented lipodystrophy Approved 2010 under trade name Egrifta Prescription required; insurance coverage variable $3,000–5,000/month retail; patient assistance

This comparison does not assign a generated winner or score.

  • FDA-Approved Use
  • HIV-associated lipodystrophy (excess abdominal fat)
  • Limited to HIV population with documented lipodystrophy
  • Approved 2010 under trade name Egrifta
  • Prescription required; insurance coverage variable
  • $3,000–5,000/month retail; patient assistance programs available
  • Off-Label Research Use
  • Metabolic syndrome, NAFLD/NASH, central obesity without HIV
  • Investigational; used in IRB-approved clinical trials
  • Off-label; not FDA-approved for metabolic syndrome
  • Requires research protocol enrollment or physician discretion
  • Research-grade peptides cost $200–400/month; clinical-grade pricing mirrors approved use
  • Mechanism Overlap
  • Visceral fat reduction via GH stimulation applies to both HIV and non-HIV populations
  • Identical pharmacology; receptor targets don't differ by disease state
  • Mechanism is universally applicable
  • Same peptide sequence used in both contexts
  • Compounded versions use identical active compound
  • Evidence Quality
  • Multiple Phase 3 RCTs in HIV lipodystrophy (JAMA, Lancet publications)
  • Smaller Phase 2 trials in metabolic syndrome; mechanistic studies in NAFLD
  • HIV data is robust; metabolic syndrome data is emerging
  • Published trials support off-label rationale but lack FDA review for this indication
  • Research institutions prioritize mechanism over approval status
  • Clinical Relevance
  • Treats cosmetic and metabolic complications of antiretroviral therapy
  • Tests whether visceral fat is causal (not just correlative) in metabolic dysfunction
  • Approval reflects historical trial funding, not mechanism specificity
  • Off-label use common in lipodystrophy-like conditions
  • Reimbursement unlikely without HIV diagnosis
  • Bottom Line
  • Approved for a narrow population, but the biology applies broadly
  • Research use is scientifically justified even without formal metabolic syndrome approval
  • Regulatory approval lags mechanistic understanding by years
  • Patients and researchers access the same compound through different regulatory pathways
  • Cost creates access barrier outside research settings
More references

Related material